Related Experiment Video
Updated: Jul 31, 2026
06:11
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
A curve-free method for phase I clinical trials.
1Dipartimento di Matematica, Politecnico di Torino, Italy. gasparin@calvino.polito.it
Biometrics
|July 6, 2000
Summary
This study introduces a curve-free method for estimating the maximum tolerated dose (MTD) in oncology clinical trials, improving upon the continual reassessment method (CRM) by directly modeling toxicity probabilities.
Area of Science:
- Biostatistics
- Clinical Trial Design
- Pharmacology
Background:
- Estimating the maximum tolerated dose (MTD) is crucial in oncology Phase I trials.
- The continual reassessment method (CRM) uses a Bayesian approach with assumed dose-toxicity curves.
- Traditional methods and CRM can be limited by curve assumptions.
Purpose of the Study:
- To present a novel curve-free method for MTD estimation.
- To demonstrate that curve assumptions in CRM can hinder efficient prior input utilization.
- To introduce a product-of-beta prior (PBP) for direct toxicity probability modeling.
Main Methods:
- Developed a curve-free Bayesian approach for MTD estimation.
- Modeled toxicity probabilities directly as an unknown multidimensional parameter.
- Introduced and applied a product-of-beta prior (PBP).
Main Results:
- The proposed curve-free method avoids restrictive dose-toxicity curve assumptions.
- The product-of-beta prior (PBP) offers logical improvements in MTD estimation.
- Simulation results illustrate practical advantages over existing CRM methods.
Conclusions:
- A curve-free approach enhances the flexibility and efficiency of MTD estimation.
- Direct modeling of toxicity probabilities with PBP is a viable alternative to CRM.
- This method offers practical improvements for oncology Phase I clinical trials.
Related Concept Videos
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:21Dose Response Curve: Conventional Versus Nonmonotonic
The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...